Schedule 2

RETRANSMISSION: Akanda Corp. Signs Share Purchase and Escrow Agreements for the Sale of Portuguese Assets to Somai Pharmaceuticals

Retrieved on: 
金曜日, 3月 1, 2024
CBPM, USD, Amend, Sale, RPK, Medicine, LDA, Patient, CBD, THC, Akanda, Schedule 2, Resolution

This strategic move underscores both companies' commitment to advancing the medical cannabis industry and enhancing patient access to high-quality cannabis treatments.

Key Points: 
  • This strategic move underscores both companies' commitment to advancing the medical cannabis industry and enhancing patient access to high-quality cannabis treatments.
  • Under the terms of the Share Purchase Agreement, Somai will acquire RPK, Akanda's indirect Portuguese subsidiary, for a total consideration of Two Million United States Dollars (USD $2,000,000).
  • The execution of the Share Purchase Agreement and Escrow Agreement follows the Amended Non-Binding Letter of Intent ("LOI") announced on February 1, 2024, and represents a crucial step towards the transaction's completion.
  • The closing of the proposed sale is subject to customary due diligence, representations, warranties, covenants, indemnities, and other closing conditions.

Red Robin Gourmet Burgers, Inc. Reports Results for the Fiscal Fourth Quarter and Fiscal Year Ended December 31, 2023

Retrieved on: 
水曜日, 2月 28, 2024
Retail, Restaurant, Bar, Food, Beverage, Investment, ID, Sale, Call Me, Red Robin, Capital expenditure, GAAP, Salad, Capital, Schedule 2

Red Robin expects the transaction to generate gross proceeds of $20 million to $26 million and to use net proceeds from the transaction to repay debt.

Key Points: 
  • Red Robin expects the transaction to generate gross proceeds of $20 million to $26 million and to use net proceeds from the transaction to repay debt.
  • Red Robin will host an investor conference call to discuss its fourth quarter and full year 2023 results, and outlook for fiscal 2024 today at 4:30 p.m.
  • Red Robin Gourmet Burgers, Inc. ( www.redrobin.com ), is a casual dining restaurant chain founded in 1969 that operates through its wholly-owned subsidiary, Red Robin International, Inc., and under the trade name, Red Robin Gourmet Burgers and Brews.
  • There are more than 500 Red Robin restaurants across the United States and Canada, including those operating under franchise agreements.

Tris Pharma Awarded Five-Year Grant of Up to $16.6M From the NIH's National Institute on Drug Abuse to Advance Cebranopadol for the Treatment of Opioid Use Disorder

Retrieved on: 
月曜日, 8月 28, 2023
Research, Mental Health, Neurology, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Ketan, Pharma, Wayne State University, Opioid, Public, Initiative, ADHD, DSM-IV codes, Opioid use disorder, OUD, FQ, Heroin, Bangladesh Technical Education Board, Pain, Cocaine, NOP, National Institute on Drug Abuse, MOP, NIDA, Pain management, Drug, Schedule 2, FDA, NIH, Disease, Pharmaceutical industry, Tris

Through the Helping to End Addiction Long-term® Initiative (NIH HEAL Initiative®), NIH has awarded grants to fund the optimization of new therapies to prevent and treat opioid use disorder (OUD).

Key Points: 
  • Through the Helping to End Addiction Long-term® Initiative (NIH HEAL Initiative®), NIH has awarded grants to fund the optimization of new therapies to prevent and treat opioid use disorder (OUD).
  • Cebranopadol is an investigational, dual nociception/orphanin FQ peptide (NOP) receptor and µ-opioid peptide (MOP) receptor agonist.
  • Further, cebranopadol has demonstrated reduced cocaine and heroin self-administration and drug-seeking behaviors, reinforcing its potential as an effective treatment for OUD.
  • The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Red Robin Gourmet Burgers, Inc. Reports Results for the Fiscal Second Quarter Ended July 9, 2023

Retrieved on: 
木曜日, 8月 17, 2023
Retail, Restaurant, Bar, Net, GAAP, ID, Red Robin, EBITDA, Schedule 2, Adjustment, Salad, Bookkeeping

Red Robin will host an investor conference call to discuss financial results for its second quarter of fiscal 2023 and outlook for fiscal 2023 today at 5:00 p.m.

Key Points: 
  • Red Robin will host an investor conference call to discuss financial results for its second quarter of fiscal 2023 and outlook for fiscal 2023 today at 5:00 p.m.
  • Red Robin Gourmet Burgers, Inc. ( www.redrobin.com ), is a casual dining restaurant chain founded in 1969 that operates through its wholly-owned subsidiary, Red Robin International, Inc., and under the trade name, Red Robin Gourmet Burgers and Brews.
  • In addition to our many burger offerings, Red Robin serves a wide array of salads, appetizers, entrees, desserts, signature beverages and Donatos® pizza at select locations.
  • There are more than 500 Red Robin restaurants across the United States and Canada, including those operating under franchise agreements.

Red Robin Gourmet Burgers, Inc. Reports Results for the Fiscal First Quarter Ended April 16, 2023

Retrieved on: 
水曜日, 5月 24, 2023
Retail, Restaurant, Bar, Food, Beverage, Net, Credit agreements in South Africa, CBRE Group, Jefferies, GAAP, ID, Red Robin, Interest, Initial, EBITDA, Documentation, Acquisition, Schedule 2, Adjustment, Conference, Cryptocurrency

During the first quarter of fiscal 2023, the Company marketed an initial tranche of 10 owned properties to investors.

Key Points: 
  • During the first quarter of fiscal 2023, the Company marketed an initial tranche of 10 owned properties to investors.
  • The transaction is expected to close in the second quarter of fiscal 2023, and generate gross proceeds of approximately $30 million.
  • Red Robin will host meetings with institutional investors at the Jefferies Consumer Conference in Nantucket, MA on June 20-21, 2023.
  • Red Robin will host an investor conference call to discuss financial results for its first quarter of fiscal 2023 and outlook for fiscal 2023 today at 5:00 p.m.

Red Robin Gourmet Burgers, Inc. Reports Results for the Fiscal Fourth Quarter and Fiscal Year Ended December 25, 2022

Retrieved on: 
火曜日, 2月 28, 2023
Retail, Restaurant, Bar, Food, Beverage, EBITDA, Interest, ID, Net operating loss, GAAP, Investment, CBRE Group, Capital, Schedule 2, Credit agreements in South Africa, Fiscal, Comparable, Capital expenditure, J. P. Morgan, Food delivery, Cryptocurrency, Bank, Video game, Bookkeeping, Adjustment

Highlights for the Fiscal Year Ended December 25, 2022 Compared to the Fiscal Year Ended December 26, 2021

Key Points: 
  • Highlights for the Fiscal Year Ended December 25, 2022 Compared to the Fiscal Year Ended December 26, 2021
    Total revenues in fiscal 2022 are approximately $1.3 billion, an increase of $104.5 million as compared to fiscal 2021.
  • GAAP loss per diluted share was $4.91 in 2022 compared to GAAP loss per diluted share of $3.19 in 2021.
  • Adjusted EBITDA(2) (a non-GAAP financial measure) is $52.8 million in fiscal 2022 versus $63.5 million in fiscal 2021.
  • Red Robin will host an investor conference call to discuss its fourth quarter and full year 2022 results, and Outlook for 2023 today at 5:00 p.m.

Caledonia Mining Corporation Plc: Completion of the acquisition of the Bilboes gold project in Zimbabwe and appointment of Executive Director

Retrieved on: 
金曜日, 1月 6, 2023
Terrorism, Technical report, Legislation, Coronavirus, NI, Metallurgy, Schedule 2, Mining, COVID-19, Ministry of Oil and Mineral Reserves (Syria), News, Transaction, Acquisition, Infection, SEDAR, Nationalization, Safety, National instrument, Insurance, Bilboes, Mineral, European Union (Withdrawal) Act 2018, Canadian Securities Administrators, MAR, Sale, NSR, Project, Risk management, Cryptocurrency, EU

Note: The information contained within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulation (EU) No.

Key Points: 
  • Note: The information contained within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulation (EU) No.
  • This news release is not an offer of the shares of Caledonia for sale in the United States or elsewhere.
  • The parties have agreed the cap at $90million (which would require the Project to produce revenues of $9billion).
  • 5Refer to technical report entitled "Caledonia Mining Corporation Plc Updated NI 43-101 Mineral Resource Report on the Maligreen Gold Project, Zimbabwe" dated November 3, 2022 prepared by Minxcon (Pty) Ltd and filed on SEDAR on November 7, 2022.

Vyripharm Enterprises Inc. held its 2022 Legislative Summit For Public Health and Public Safety with Keynote Speaker Congressman Dan Crenshaw

Retrieved on: 
木曜日, 9月 15, 2022
Research, Cannabis, Pharmaceutical, White House, Federal Government, Agriculture, Natural Resources, Other Policy Issues, Advocacy Group Opinion, Science, Biotechnology, Alternative Medicine, Health, Public Policy, Government, Bureau of Oceans and International Environmental and Scientific Affairs, Safety, Lists of diseases, Federal, TMC, Cannabinoid, Industry, Schedule 2, Health, Program, GSC Enterprises, Inc., Cancer, The Texas Medical Center Library, Senate, State, Quality of life, Â, Public health, Toxicity, Congress, Government, Texas State University, Multimedia, Texas Medical Center, Infection, Medical device, Drug, Pharmaceutical industry, Cannabis

Vyripharm Enterprises Inc. and BIZPAC.US hosted the First Annual Vyripharm Public Health and Safety Legislative Reception on August 31, 2022 at the Texas Medical Center (TMC) Institute Innovation Factory, TMC's 1st phase biotech incubator and accelerator.

Key Points: 
  • Vyripharm Enterprises Inc. and BIZPAC.US hosted the First Annual Vyripharm Public Health and Safety Legislative Reception on August 31, 2022 at the Texas Medical Center (TMC) Institute Innovation Factory, TMC's 1st phase biotech incubator and accelerator.
  • This will not only protect the publics health and safety, but also the U.S. legal cannabis market as well.
  • Our aim is to ensure the security of agri-biopharmaceuticals through our commitment to public health and safety.
  • Vyripharm Enterprises, Inc. holds foundational patents in safety certification and regulation of cannabinoids in the United States and 40 other countries around the world.

Trevena Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical

Retrieved on: 
木曜日, 1月 27, 2022
U.S. Securities and Exchange Commission, Acute respiratory distress syndrome, Maintenance, PCA, SEC, Central nervous system disease, Health, IV, NMPA, Security (finance), Migraine, Patient, Death, GLOBE, CNS, Syndrome, National Medical Products Administration, Pharmacokinetics, Workforce, Safety, AND, Central nervous system, Opioid, Research, Benzodiazepine, TRV734, Pregnancy, License, Abuse, Company, Analgesic, Anesthetic, Schedule 2, Trevena Inc, Hospital, Food and Drug Administration Amendments Act of 2007, CEO, FDA, Food, Risk, Coma, Trevena, COVID-19, Hypoventilation, Schedule, Pain, Opioid use disorder, Private Securities Litigation Reform Act, RISK, Nobel Prize, Drug, Epilepsy, NDA, Pharmaceutical industry, Liquor

CHESTERBROOK, Pa., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that China’s National Medical Products Administration (NMPA) has accepted submission of a New Drug Application (NDA) for oliceridine injection. The NDA was submitted by Trevena’s partner, Jiangsu Nhwa Pharmaceutical, and follows completion by Nhwa of a Phase 3 bridging trial for OLINVYK (oliceridine) injection, a novel IV analgesic that has been approved in the United States by the Food and Drug Administration (FDA) for use in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.

Key Points: 
  • Trevena executed an exclusive License Agreement in 2018 with Nhwa to develop, manufacture, and commercialize OLINVYK in China and is eligible to receive regulatory and commercial milestone payments as well a 10% royalty on net sales in China.
  • The launch of OLINVYK in China, if approved by the NMPA, will help to address the significant unmet need in acute pain management.
  • Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders.
  • Jiangsu Nhwa Pharmaceutical Co., Ltd., is a Chinese pharmaceutical company committed to setting new standards in CNS healthcare.

iCoreConnect Announces Kansas Dental Association Endorsement and Washington State Dental Association Recommendation as Continued Monthly Recurring Revenue and Subscriptions Expand at Record Levels

Retrieved on: 
火曜日, 1月 18, 2022
Schedule 2, News, OTCQB, Human, CEO, Revenue, KDA, Solution, GLOBE, Review, WSDA, Dentist, Dentistry, Company, Software as a service, Workflow, Substance-related disorder, Judgement, Patient safety, Pharmaceutical industry

iCoreRx integrates with most major practice management systems in the United States, removing challenges, improving patient safety and better protecting dental practices.

Key Points: 
  • iCoreRx integrates with most major practice management systems in the United States, removing challenges, improving patient safety and better protecting dental practices.
  • KDA provides member dentists with legislative advocacy, timely news updates, and endorsed programs and services.
  • Kansas law for prescribing controlled substances changed on July 1, 2021, requiring electronic prescriptions for Schedule II-V drugs.
  • As of January 1, 2022, state law in Washington requires doctors to electronically prescribe Schedule II-V controlled substances.